Plant-based Excipients Market Size & Growth Forecast 2026–2035, By Segments (Chemical Nature, Applications and Function), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Plant-based Excipients Market size was over USD 1.99 Billion in 2025 and is likely to grow at a 4.4% CAGR between 2026 and 2035, attaining USD 3.06 Billion by 2035. The industry revenue for 2026 is calculated at USD 2.07 billion.

• Base Year Value (2025): USD 1.99 Billion
• CAGR (2026-2035): 4.4%
• Forecast Year Value (2035): USD 3.06 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Plant-based Excipients Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 40.81% of the market in 2025, supported by a strong pharmaceutical manufacturing base, validated ingredient systems, and consistent demand for plant-derived excipients in large-scale production.
  • Asia Pacific is projected to grow at a 5.02% CAGR as pharmaceutical manufacturing expands, domestic production increases, and plant-derived excipients gain wider adoption in high-volume formulations.

• Segment Momentum:

  • Carbohydrates held a 22.78% share in 2025 because they provide versatile plant-derived excipients that support tablet structure, formulation stability, and efficient pharmaceutical manufacturing across multiple dosage forms.
  • Film Forming & Coating Agents are expanding fastest as pharmaceutical manufacturers increasingly prioritize protective coatings, improved swallowability, surface protection, and product differentiation in finished dosage forms.

• Market Expansion Drivers:

  • Rising demand for vegan pharmaceuticals driving adoption of plant-derived excipients in drug formulations.
  • Regulatory support for animal-free and halal-compliant drug ingredients boosting market penetration.
  • Pharmaceutical R&D expansion accelerating innovation in natural excipient-based drug delivery systems.

• Leading Market Participants:

  Prominent companies in the plant-based excipients market include Roquette Frères (France), BASF SE (Germany), Lonza Group AG (Switzerland), DFE Pharma (Germany), Evonik Industries AG (Germany), JRS Pharma GmbH & Co. KG (Germany), Ashland Inc. (United States), Croda International Plc (United Kingdom), International Flavors & Fragrances Inc. (United States), Colorcon Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.99 Billion
  • Projected Market Size: USD 3.06 Billion by 2035
  • Growth Forecasts: 4.4% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Carbohydrates (Chemical Nature) | Binders & Diluents (Applications and Function)
  • Emerging Opportunity Segment: Carbohydrates (Chemical Nature) | Film Forming & Coating Agents (Applications and Function)

Market Growth Drivers and Industry Trends

Rising demand for vegan pharmaceuticals driving adoption of plant-derived excipients in drug formulations

As pharmaceutical companies broaden portfolios to align with vegan, vegetarian, and clean-label healthcare preferences, excipient selection is becoming a formulation-level differentiator rather than a purely technical procurement choice. In the plant-based excipients market, this shift is driving demand for starches, celluloses, gums, and other plant-derived functional ingredients that allow manufacturers to avoid animal-origin binders, capsules, stabilizers, and fillers while maintaining product performance. The effect is especially visible in oral solid doses and nutraceutical-pharma crossover products, where brand positioning, patient acceptability, and ingredient transparency increasingly shape development and sourcing decisions, reinforcing market demand for plant-origin alternatives that can be integrated into existing manufacturing workflows.

Regulatory support for animal-free and halal-compliant drug ingredients boosting market penetration

Regulatory and certification frameworks that favor animal-free, vegetarian, and halal-compliant ingredients are making plant-origin excipients more commercially attractive during product development and market access planning. For the plant-based excipients market, the practical impact comes through procurement standardization and reduced friction in launching products intended for diverse patient populations and export geographies with strict ingredient acceptability requirements. Manufacturers are more frequently choosing plant-derived excipients early in formulation design to simplify compliance documentation, avoid reformulation risks tied to animal-origin inputs, and strengthen label claims that matter in institutional purchasing and consumer-facing healthcare categories, increasing market penetration through specification-driven adoption.

Pharmaceutical R&D expansion accelerating innovation in natural excipient-based drug delivery systems

Broader pharmaceutical R&D activity is increasing attention on excipients not only as inert components but as tools for improving solubility, release control, stability, and patient experience, which is opening more space for natural materials in advanced formulations. In the plant-based excipients market, this is supporting market expansion as developers test plant-derived polymers, fibers, and hydrocolloids in modified-release systems, taste-masking formats, and bioavailability-enhancing platforms that fit current preferences for cleaner ingredient profiles. As formulation scientists validate these materials in more complex delivery applications, plant-based excipients move from commodity inputs toward higher-value functional roles, driving market development through deeper integration into drug design rather than simple ingredient substitution.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Growing use of plant-based excipients in pharmaceuticals	1.50%	Short term (≤ 2 yrs)	North America, Europe (spillover: Asia Pacific)	Medium	Fast
Adoption in nutraceutical and functional food formulations	1.50%	Medium term (2–5 yrs)	Europe, Asia Pacific (spillover: North America)	Medium	Moderate
Development of sustainable and certified excipients	1.40%	Long term (5+ yrs)	North America, Europe (spillover: Asia Pacific)	High	Slow
Rising demand for vegan pharmaceuticals driving adoption of plant-derived excipients in drug formulations	2.00%	High	North America, Europe	High	Mid Term
Regulatory support for animal-free and halal-compliant drug ingredients boosting market penetration	1.80%	High	Asia Pacific, Middle East	High	Mid Term
Pharmaceutical R&D expansion accelerating innovation in natural excipient-based drug delivery systems	1.50%	Moderate	North America, Asia Pacific	Medium	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional position in 2025, accounting for a 40.81% share of the plant-based excipients market. This leadership is supported by the region’s established pharmaceutical manufacturing base, where excipient selection is closely tied to formulation performance, regulatory compliance, and supply consistency. Demand is aided by manufacturers’ preference for well-validated ingredient systems in oral solid dosage forms, nutraceuticals, and clean-label product development, which keeps procurement concentrated among reliable plant-derived inputs and sustains high market activity across large-volume production settings.

Asia Pacific is projected to expand at a 5.02% CAGR over the forecast period in the plant-based excipients market, driven by the ongoing buildout of pharmaceutical and supplement manufacturing capacity across the region. Growth is accelerating as producers increasingly incorporate plant-derived excipients into cost-sensitive, high-volume formulations while responding to broader demand for naturally sourced ingredients. The region’s momentum is also linked to rising domestic production and formulation activity, which increases practical adoption of these excipients in everyday manufacturing rather than limiting use to niche product lines.

Key Country Insights

United States

Natural Formulation Demand

The U.S. plant-based excipients market is expanding as pharmaceutical manufacturers incorporate naturally derived ingredients into oral and topical formulations. Companies in the U.S. prioritize functional performance, regulatory compliance, and dependable botanical raw material sourcing.

Japan

Functional Ingredient Innovation

Japan develops plant-based excipients with improved stability, controlled release, and compatibility for advanced pharmaceutical formulations. Japanese manufacturers focus on formulation efficiency while maintaining stringent quality expectations for healthcare applications.

South Korea

Biopharma Ingredient Expansion

South Korea is increasing the adoption of plant-based excipients alongside growth in pharmaceutical manufacturing and biopharmaceutical development. Local suppliers strengthen formulation support services and diversify botanical ingredient portfolios for drug manufacturers.

Germany

Pharmaceutical Quality Standards

Germany emphasizes plant-based excipients that meet rigorous pharmaceutical quality and manufacturing requirements. German suppliers invest in validated production processes and documentation to support formulation consistency across prescription and over-the-counter products.

France

Botanical Sourcing Expertise

France leverages expertise in botanical ingredients to support pharmaceutical excipient development using plant-derived materials. French manufacturers emphasize traceable sourcing and formulation performance that aligns with evolving industry quality expectations.

Italy

Natural Ingredient Processing

Italy combines botanical processing capabilities with pharmaceutical manufacturing to expand plant-based excipient availability. Italian producers focus on ingredient purity, functional consistency, and collaboration with formulation developers seeking naturally derived alternatives.

Segment Leadership and Growth Trends

  Chemical Nature Segment Analysis: Carbohydrates (Largest & Fastest-Growing Segment)

Carbohydrates held a 22.78% share of the plant-based excipients market in 2025, making them the leading chemical nature segment while also sustaining the fastest growth momentum. Their position is supported by broad usability across formulation needs, where carbohydrate-based excipients serve as practical base materials for tablet structure, stability, and processing efficiency. That same versatility is also driving continued expansion in the plant-based excipients market, as manufacturers favor excipient classes that can support multiple dosage form requirements without moving away from plant-derived inputs.

Applications and Function Segment Analysis: Binders & Diluents (Largest Segment) vs Film Forming & Coating Agents (Fastest-Growing Segment)

Within the plant-based excipients market, Binders & Diluents accounted for a 22.36% share in 2025, reflecting their leading role across routine pharmaceutical formulation and manufacturing processes. Their leadership is underpinned by their direct involvement in bulk formation, compressibility, and dosage consistency, which makes them essential in high-volume solid dosage production. Because these functions sit at the core of everyday manufacturing requirements, demand remains broad and steady for plant-based excipients used as binders and diluents.

Film Forming & Coating Agents are emerging as the fastest-growing application segment in the plant-based excipients market as formulators place greater emphasis on protective coatings, appearance control, and performance optimization in finished dosage forms. Growth is outpacing other functions because coating-related requirements become more important as product differentiation, swallowability, and surface protection gain practical importance in drug delivery. This creates stronger momentum for plant-based excipients that can support coating performance while aligning with plant-derived formulation preferences.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Chemical Nature	Carbohydrates, Proteins, Polymers, Minerals, Glycoside & Waxes, Esters, Ethers & Carboxylic Acids, Others	Carbohydrates	Carbohydrates
Applications and Function	Binders & Diluents, Glidants, Lubricants & Disintegrants, Film Forming & Coating Agents, Plasticizers, Suspending Agents, Preservatives & Antioxidants, Colorants & Flavoring Agents	Binders & Diluents	Film Forming & Coating Agents

Competitive Landscape and Market Positioning

Prominent players in the plant-based excipients market:

1. Roquette Frères (France)

2. BASF SE (Germany)

3. Lonza Group AG (Switzerland)

4. DFE Pharma (Germany)

5. Evonik Industries AG (Germany)

6. JRS Pharma GmbH & Co. KG (Germany)

7. Ashland Inc. (United States)

8. Croda International Plc (United Kingdom)

9. International Flavors & Fragrances Inc. (United States)

10. Colorcon Inc. (United States)

The plant-based excipients market is evolving through a noticeable shift toward cleaner formulations and naturally derived functional ingredients that align with modern formulation needs. Innovation activity is increasingly focused on expanding application versatility across pharmaceuticals and nutraceuticals, supported by ongoing development of new excipient functionalities. Collaborative development efforts and continuous product enhancements are enabling broader substitution of synthetic components, improving both safety profiles and regulatory alignment. Rising preference for plant-derived inputs is further reinforcing reformulation strategies, encouraging suppliers to differentiate through performance consistency and sourcing transparency within the plant-based excipients market.

Industry Development/News

Company Name	Date	Key Development
Roquette	Nov-25	Roquette showcased its plant-based excipient portfolio and dosage technologies designed to support formulation of nutrient-dense supplements for consumers using GLP-1 therapies. The development highlights the company's continued focus on multifunctional, plant-derived excipients that enable more adaptable and sustainable nutraceutical formulations.
JRS PHARMA	Nov-22	JRS PHARMA launched LUBRITAB RBW, an all-natural plant-based excipient developed as a lubricant for tablet and capsule formulations. Compatible with direct compression, continuous manufacturing, and dry or wet granulation processes, the product expands the company's portfolio of naturally derived pharmaceutical excipients.